For example, sorafenib, a multi-kinase inhibitor that acts on epidermal growth factor receptor (EGFR) family members and downstream signaling partners, tends to achieve better efficacy when applied to BRAF wild-type CRC patients [27]. The gene discussed is EGFR; the disease is colorectal carcinoma.